Organogenesis Inc. acquired Dermagraft assets from Shire Regenerative Medicine, Inc. for $300 million on January 16, 2014. Under the terms of the agreement, Shire Regenerative Medicine will receive no upfront payment but is entitled to receive total milestone payments of up to $300 million in cash if Organogenesis Inc. meets certain annual net sales targets during the five consecutive calendar years ending with the calendar year ending December 31, 2018. Credit Suisse acted as financial advisor to Organogenesis. Foley Hoag LLP acted as legal advisor for Organogenesis Inc. Lazard Group LLC acted as financial advisor and William J. Chudd, Peter M. Lamb, Katherine Tsai, Michael Mollerus,Thomas D. Phelan, Cynthia Akard, Ronan P. Harty, Michael N. Sohn, Pritesh P. Shah, and Susan D. Kennedy of Davis Polk & Wardwell LLP acted as legal advisors for Shire Regenerative Medicine, Inc.


Organogenesis Inc. completed the acquisition of Dermagraft assets from Shire Regenerative Medicine, Inc. on January 16, 2014.